By Armen Gevorgyan, MD From: oncodaily.com For years, hormone receptor–positive (HR+) metastatic breast cancer was described as “indolent.” It wasn’t. It was slower than triple-negative disease. It was more responsive to endocrine therapy. But resistance was inevitable. Median overall survival rarely crossed four years in metastatic settings. Treatment sequencing revolved around endocrine therapy first, chemotherapy later. Then came the MONALEESA …
Polytherapy improves blood pressure control and survival in metastatic breast cancer
Source: Kaiser Permanente From: news-medical.net Women with metastatic breast cancer often face multiple chronic conditions, and high blood pressure is among the most common. Nearly half of women in this study population had hypertension at diagnosis, with even higher rates among Black and Hispanic patients. Researchers sought to understand whether more effective hypertension management could improve survival. The study found …
Metastatic Breast Cancer: Screening Increases 10-Year Survival from 20% to 60%
From: .insideprecisionmedicine.com A new study shows that it may never be too late to benefit from breast cancer screening. Published today in the Journal of the National Cancer Institute, the study reports that women with stage IV metastatic breast cancer detected through screening have a 60% chance of survival, compared to 20% for those not detected through screening. “There is …
A New First-line Option for Metastatic Breast Cancer
From: aacr.org Fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab was approved to treat metastatic HER2-positive breast cancer. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for patients with newly diagnosed human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has either metastasized or cannot be removed with surgery. Concurrently, two tests …
Triple negative breast cancer cells use new strategy to boost metastatic ability
Source: Baylor College of Medicine From: news-medical.net Researchers at Baylor College of Medicine have uncovered a strategy that triple negative breast cancer (TNBC) cells use to boost their ability to metastasize, or spread to other organs. Metastasis is the leading cause of cancer-related deaths and scientists are investigating ways to prevent it. These findings, published in Nature Communications, highlight new …
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
By: Sabrina Serani From: targetedonc.com Key Takeaways Multiomic profiling, including whole exome and transcriptome sequencing, offers prognostic value beyond standard HER2 immunohistochemistry. HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. Elevated ABCC1 expression is associated with poorer outcomes, indicating its role in resistance to T-DXd. Integrating multiomic data into clinical practice …
Tucatinib Enhances First-Line Maintenance Outcomes in HER2-Positive Metastatic Breast Cancer
By: Alexandra Gerlach, Editor From: pharmacytimes.com Key Takeaways Tucatinib added to trastuzumab and pertuzumab improved PFS by 8.6 months in patients with HER2+ metastatic breast cancer. The HER2CLIMB-05 trial showed consistent PFS benefits across subgroups, including those with brain metastases. Common adverse events with tucatinib included diarrhea and elevated liver enzymes, with manageable severity. Tucatinib integration into first-line maintenance therapy …
Evolving Strategies in the Management of HR+, HER2– Metastatic Breast Cancer
By: Guilherme Nader-Marta, MD, Erica L. Mayer, MD, MPH From: onclive.com Key Takeaways Sacituzumab govitecan improved PFS in untreated advanced TNBC patients not eligible for PD-(L)1 inhibitors, as shown in the ASCENT-03 trial. The ASCENT-04 trial demonstrated enhanced PFS with sacituzumab govitecan plus pembrolizumab in PD-L1–positive TNBC compared to chemotherapy plus pembrolizumab. Safety analysis indicated a favorable benefit/risk profile for …
FDA OKs Study Progression of (Z)-Endoxifen in Metastatic Breast Cancer
By: Roman Fabbricatore From: cancernetwork.com The FDA issued a “Study May Proceed” letter for a new study investigating oral (Z)-endoxifen in patients with metastatic breast cancer, according to a news release from the developer, Atossa Therapeutics.1 The subject of a recent investigational new drug (IND) application, the ongoing study aims to provide a new therapeutic strategy for patients with estrogen …
Where you live may be fueling aggressive breast cancer
Source: University of Miami Miller School of Medicine From: sciencedaily.com New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that women who live near federally designated Superfund sites face a higher risk of developing aggressive forms of breast cancer — including triple-negative breast cancer, which is especially difficult to treat. Previous research …